BCG immunotherapy of bladder cancer: 20 years on

  title={BCG immunotherapy of bladder cancer: 20 years on},
  author={A. Alexandroff and A. Jackson and M. O'Donnell and K. James},
  journal={The Lancet},
  • A. Alexandroff, A. Jackson, +1 author K. James
  • Published 1999
  • Medicine
  • The Lancet
  • 1The situation is similar for most industrialised western nations, with incidence rates of 18 to 30 new cases per 10 0 000 men placing bladder cancer among the top five cancers in this sex. It is unclear why women are affected a third to a quarter less often than men. In 75% of patients the disease is diagnosed in its early superficial stage, usually as a result of gross or microscopic blood in the urine. However, with an overall 65% recurrence rate and 30% progression rate, even these patients… CONTINUE READING
    426 Citations
    Immunotherapy of Renal and Bladder Cancers
    Immunotherapy for bladder cancer
    • 129
    • PDF
    Predicting Disease Course in Bladder Cancer: STAG2 as a Prognostic Biomarker
    Medical Management of Patients with Refractory Carcinoma In Situ of the Bladder
    • 16


    The epidemiology of bladder cancer. A second look
    • 281
    • PDF
    Intravesical BCG: Current results, natural history and implicants for urothelial cancer prevention
    • H. Herr
    • Medicine
    • Journal of cellular biochemistry. Supplement
    • 1992
    • 39
    Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression.
    • R. Kaempfer, L. Gerez, +4 authors A. Shapiro
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 1996
    • 87
    Expression of mage genes in transitional‐cell carcinomas of the urinary bladder
    • 145